Stefan G. Kathman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stefan G. Kathman has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ziyang Xu
Perelman School of Medicine University of Pennsylvania Philadelphia PA USA
4 shared publications - Alexander V. Statsyuk
A Department of Chemistry , Center for Molecular Innovation and Drug Discovery , Chemistry of Life Processes Institute , Northwestern University , Silverman Hall, 2145 Sheridan Road , Evanston , Illinois 60208 , USA
3 shared publications - Alexander V. Statsyuk
Department of Pharmacological and Pharmaceutical Sciences, University of Houston College of Pharmacy
3 shared publications - Benjamin F. Cravatt
Department of Chemistry, Scripps Research, La Jolla, USA
3 shared publications - Alexander V. Statsyuk
University of Houston, College of Pharmacy, Houston, TX, USA.
2 shared publications - Caroline Kisker
University of Würzburg
2 shared publications
Latest Publications
- Open Access
- 16 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71051
NONO Maintains SREBP ‐Regulated Cholesterol Biosynthesis via RNA Binding in Neuroblastoma
High‐risk neuroblastoma is associated with upregulation of cholesterol biosynthesis through increased expression of sterol regulatory element—binding protein (SREBP). NONO, a multifunctional nuclear RNA binding protein, is an established oncogene in neuroblastoma and can stabilize SREBP in breast cancer. Hence, here we addressed the unexplored question of NONO regulation of SREBP in neuroblastoma. We show NONO knockdown reduces cholesterol in neuroblastoma patient‐derived tumor cell lines and high‐risk neuroblastoma KELLY cells. NONO knockdown also reduces mRNA and protein expression of SREBP family members in KELLY cells. RNA‐seq of NONO knockdown confirmed cholesterol synthesis pathway genes are downregulated. Further, only overexpression of NONO wild‐type, rather than NONO mutant lacking the RNA recognition motif 1, could elevate SREBP levels after endogenous NONO knockdown, revealing the importance of NONO RNA binding activity. Finally, (R)‐SKBG‐1, a small molecule that modulates the RNA binding activity of NONO, hence altering its subnuclear distribution, significantly decreased cholesterol levels and SREBP target gene expression in KELLY cells. These results lend weight to manipulating NONO RNA binding as a potential therapeutic avenue for treating aggressive neuroblastoma.
- 16 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71051
Open AccessNONO Maintains SREBP ‐Regulated Cholesterol Biosynthesis via RNA Binding in Neuroblastoma
High‐risk neuroblastoma is associated with upregulation of cholesterol biosynthesis through increased expression of sterol regulatory element—binding protein (SREBP). NONO, a multifunctional nuclear RNA binding protein, is an established oncogene in neuroblastoma and can stabilize SREBP in breast cancer. Hence, here we addressed the unexplored question of NONO regulation of SREBP in neuroblastoma. We show NONO knockdown reduces cholesterol in neuroblastoma patient‐derived tumor cell lines and high‐risk neuroblastoma KELLY cells. NONO knockdown also reduces mRNA and protein expression of SREBP family members in KELLY cells. RNA‐seq of NONO knockdown confirmed cholesterol synthesis pathway genes are downregulated. Further, only overexpression of NONO wild‐type, rather than NONO mutant lacking the RNA recognition motif 1, could elevate SREBP levels after endogenous NONO knockdown, revealing the importance of NONO RNA binding activity. Finally, (R)‐SKBG‐1, a small molecule that modulates the RNA binding activity of NONO, hence altering its subnuclear distribution, significantly decreased cholesterol levels and SREBP target gene expression in KELLY cells. These results lend weight to manipulating NONO RNA binding as a potential therapeutic avenue for treating aggressive neuroblastoma.
- Top Cited Papers
- 2 March 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (7) , 825-836
Remodeling oncogenic transcriptomes by small molecules targeting NONO
Much of the human proteome is involved in mRNA homeostasis, but most RNA-binding proteins lack chemical probes. Here we identify electrophilic small molecules that rapidly and stereoselectively decrease the expression of transcripts encoding the androgen receptor and its splice variants in prostate cancer cells. We show by chemical proteomics that the compounds engage C145 of the RNA-binding protein NONO. Broader profiling revealed that covalent NONO ligands suppress an array of cancer-relevant genes and impair cancer cell proliferation. Surprisingly, these effects were not observed in cells genetically disrupted for NONO, which were instead resistant to NONO ligands. Reintroduction of wild-type NONO, but not a C145S mutant, restored ligand sensitivity in NONO-disrupted cells. The ligands promoted NONO accumulation in nuclear foci and stabilized NONO–RNA interactions, supporting a trapping mechanism that may prevent compensatory action of paralog proteins PSPC1 and SFPQ. These findings show that NONO can be co-opted by covalent small molecules to suppress protumorigenic transcriptional networks.
- 2 March 2023
- Published by Springer Nature in Nature Chemical Biology
- Vol. 19 (7) , 825-836
Top Cited PapersRemodeling oncogenic transcriptomes by small molecules targeting NONO
Much of the human proteome is involved in mRNA homeostasis, but most RNA-binding proteins lack chemical probes. Here we identify electrophilic small molecules that rapidly and stereoselectively decrease the expression of transcripts encoding the androgen receptor and its splice variants in prostate cancer cells. We show by chemical proteomics that the compounds engage C145 of the RNA-binding protein NONO. Broader profiling revealed that covalent NONO ligands suppress an array of cancer-relevant genes and impair cancer cell proliferation. Surprisingly, these effects were not observed in cells genetically disrupted for NONO, which were instead resistant to NONO ligands. Reintroduction of wild-type NONO, but not a C145S mutant, restored ligand sensitivity in NONO-disrupted cells. The ligands promoted NONO accumulation in nuclear foci and stabilized NONO–RNA interactions, supporting a trapping mechanism that may prevent compensatory action of paralog proteins PSPC1 and SFPQ. These findings show that NONO can be co-opted by covalent small molecules to suppress protumorigenic transcriptional networks.
- 1 May 2020
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (5) , 482-483
A masked zinger to block GPX4
Ferroptosis induced by GPX4 inhibition offers promise for killing drug-resistant cancer cells, yet current GPX4 inhibitors lack selectivity. The discovery of masked nitrile oxide electrophiles as selective prodrug inhibitors of GPX4 points to an attractive path for chemically inducing ferroptosis.
- 1 May 2020
- Published by Springer Nature in Nature Chemical Biology
- Vol. 16 (5) , 482-483
A masked zinger to block GPX4
Ferroptosis induced by GPX4 inhibition offers promise for killing drug-resistant cancer cells, yet current GPX4 inhibitors lack selectivity. The discovery of masked nitrile oxide electrophiles as selective prodrug inhibitors of GPX4 points to an attractive path for chemically inducing ferroptosis.
- 23 March 2020
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 15 (4) , 1036-1049
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
BRD4, a member of the bromodomain and extraterminal domain (BET) family, has emerged as a promising epigenetic target in cancer and inflammatory disorders. All reported BET family ligands bind within the bromodomain acetyl-lysine binding sites and competitively inhibit BET protein interaction with acetylated chromatin. Alternative chemical probes that act orthogonally to the highly-conserved acetyl-lysine binding sites may exhibit selectivity within the BET family and avoid recently reported toxicity in clinical trials of BET bromodomain inhibitors. Here, we report the first identification of a ligandable site on a bromodomain outside the acetyl-lysine binding site. Inspired by our computational prediction of hotspots adjacent to nonhomologous cysteine residues within the C-terminal BRD4 bromodomain (BRD4-BD2), we performed a mid-throughput mass spectrometry screen to identify cysteine-reactive fragments that covalently and selectively modify BRD4. Subsequent mass spectrometry, NMR and computational docking analyses of electrophilic fragment hits revealed a novel ligandable site near Cys356 that is unique to BRD4 among human bromodomains. This site is orthogonal to the BRD4-BD2 acetyl-lysine binding site as Cys356 modification did not impact binding of the pan-BET bromodomain inhibitor JQ1 in fluorescence polarization assays nor an acetylated histone peptide in AlphaScreen assays. Finally, we tethered our top-performing covalent fragment to JQ1 and performed NanoBRET assays to provide proof of principle that this orthogonal site can be covalently targeted in intact human cells. Overall, we demonstrate the potential of targeting sites orthogonal to bromodomain acetyl-lysine binding sites to develop bivalent and covalent inhibitors that displace BRD4 from chromatin.
- 23 March 2020
- Published by American Chemical Society (ACS) in ACS Chemical Biology
- Vol. 15 (4) , 1036-1049
Covalent-Fragment Screening of BRD4 Identifies a Ligandable Site Orthogonal to the Acetyl-Lysine Binding Sites
BRD4, a member of the bromodomain and extraterminal domain (BET) family, has emerged as a promising epigenetic target in cancer and inflammatory disorders. All reported BET family ligands bind within the bromodomain acetyl-lysine binding sites and competitively inhibit BET protein interaction with acetylated chromatin. Alternative chemical probes that act orthogonally to the highly-conserved acetyl-lysine binding sites may exhibit selectivity within the BET family and avoid recently reported toxicity in clinical trials of BET bromodomain inhibitors. Here, we report the first identification of a ligandable site on a bromodomain outside the acetyl-lysine binding site. Inspired by our computational prediction of hotspots adjacent to nonhomologous cysteine residues within the C-terminal BRD4 bromodomain (BRD4-BD2), we performed a mid-throughput mass spectrometry screen to identify cysteine-reactive fragments that covalently and selectively modify BRD4. Subsequent mass spectrometry, NMR and computational docking analyses of electrophilic fragment hits revealed a novel ligandable site near Cys356 that is unique to BRD4 among human bromodomains. This site is orthogonal to the BRD4-BD2 acetyl-lysine binding site as Cys356 modification did not impact binding of the pan-BET bromodomain inhibitor JQ1 in fluorescence polarization assays nor an acetylated histone peptide in AlphaScreen assays. Finally, we tethered our top-performing covalent fragment to JQ1 and performed NanoBRET assays to provide proof of principle that this orthogonal site can be covalently targeted in intact human cells. Overall, we demonstrate the potential of targeting sites orthogonal to bromodomain acetyl-lysine binding sites to develop bivalent and covalent inhibitors that displace BRD4 from chromatin.
- 9 May 2019
- Published by Springer Nature
- Vol. 1967, 245-262
Methodology for Identification of Cysteine-Reactive Covalent Inhibitors
Covalent fragments are an emerging technology to discover covalent ligands in target-based or phenotypic screens. Here we describe screening of cysteine-reactive covalent fragments against a protein of interest using mass spectrometry or enzymatic methods.
- 9 May 2019
- Published by Springer Nature
- Vol. 1967, 245-262
Methodology for Identification of Cysteine-Reactive Covalent Inhibitors
Covalent fragments are an emerging technology to discover covalent ligands in target-based or phenotypic screens. Here we describe screening of cysteine-reactive covalent fragments against a protein of interest using mass spectrometry or enzymatic methods.
- 1 January 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (1) , 36-39
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments
- 1 January 2019
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 29 (1) , 36-39
Discovery of covalent enzyme inhibitors using virtual docking of covalent fragments
- Open Access
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Front Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 8 October 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2012
Open AccessFront Cover: Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis (ChemMedChem 19/2018)
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.
- 6 September 2018
- Published by Wiley in ChemMedChem
- Vol. 13 (19) , 2014-2023
Structural Basis of Substrate Recognition and Covalent Inhibition of Cdu1 from Chlamydia trachomatis
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target‐hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine‐based inhibitors identified represent the first active‐site‐directed small‐molecule inhibitors of Cdu1. High‐resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active‐site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure‐guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.
- 28 January 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (4) , 576-585
Covalent tethering of fragments for covalent probe discovery
Design rules for covalent fragment libraries are outlined.
- 28 January 2016
- Published by Royal Society of Chemistry (RSC) in MedChemComm
- Vol. 7 (4) , 576-585
Covalent tethering of fragments for covalent probe discovery
Design rules for covalent fragment libraries are outlined.
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (20) , 4509-4512
Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain
- 1 October 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (20) , 4509-4512
Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain